128359-99-9

Upstream product

• 153870-09-8 (S)-1-(benzyloxycarbonyl)-5-[(tert-butyldimethylsilyl)oxymethyl]-2-pyrrolidinone 
• 6216-63-3 N-Cbz-Prolinol 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 59936-29-7 (S)-N-(tert-butoxycarbonyl)proline methyl ester 
• 69610-40-8 N-(tert-butoxycarbonyl)-L-prolinol 

Downstream Products

• 134756-75-5 (2S)-2-({[(tert-butyl)(dimethyl)silyl]oxy}methyl)pyrrolidine 

Relevant academic research and scientific papers

SUBSTITUTED OXOTREMORINE DERIVATIVES

This disclosure describes novel substituted oxotremorine derivatives of formula I having nitrogen, oxygen or sulfur groups and the prodrug forms of these derivatives. The compounds have cholinergic activity. Also disclosed are methods for treating diseases of the central nervous system in mammals employing the compounds, pharmaceutical preparations containing the compounds and the processes for the production of the compounds. STR1

Lewis acid-induced internal proton return in enolate complexes with chiral amines

Treatment of a 1:1:1 mixture of enolate 5:amine 6:lithium amide 7 with BF3·OEt2 affords the naproxen amide 4a with an enantiomer excess of 77% (>90% yield). The result is attributed to Lewis acid-induced internal proton return (ipr)

Substituted oxotremorine derivatives and pharmaceutical use thereof

This disclosure describes novel substituted oxotremorine derivatives of formula I having nitrogen, oxygen or sulfur groups and the prodrug forms of these derivatives. The compounds have cholinergic activity. Also disclosed are methods for treating disease